Drug:
Reaction: DEATH
20250101 - 20251231
No. 101 - 200
No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
101 | 25141122 |
US |
1 | |
Death, Pneumonia, |
||||
LECANEMAB, |
||||
102 | 25141134 |
CA |
1 | |
Death, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
103 | 25141135 |
US |
85 | 2 |
Death, |
||||
RIOCIGUAT, RIOCIGUAT, FEXOFENADINE HYDROCHLORIDE, APIXABAN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, THIAMINE HYDROCHLORIDE, RIBOFLAVIN 5 PHOSPHATE SODIUM, DEXPANTHENOL AND NIACINAMIDE, VITAMIN E, CREAM, ALBUTEROL SULFATE, METOLAZONE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, OXYGEN, 0XYGEN, MONTELUKAST SODIUM, MONTELUKAST, DAPAGLIFLOZIN, ACETAMINOPHEN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ROSUVASTATIN CALCIUM, |
||||
104 | 25141138 |
NL |
1 | |
Death, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
105 | 25141140 |
NL |
1 | |
Death, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
106 | 25141141 |
US |
||
Death, |
||||
RAVULIZUMAB, |
||||
107 | 25141201 |
MA |
2 | |
Death, |
||||
PALBOCICLIB, |
||||
108 | 25141202 |
CA |
40 | 1 |
Death, |
||||
ENCORAFENIB, CETUXIMAB, |
||||
109 | 25141205 |
MA |
2 | |
Death, |
||||
PALBOCICLIB, |
||||
110 | 25141209 |
IN |
46 | 2 |
Death, Swelling face, Ecchymosis, Weight decreased, Pain, Tenderness, Rash, Blood triglycerides increased, Blood cholesterol increased, Blood glucose increased, Weight increased, Oedema, |
||||
LORLATINIB, LORLATINIB, LORLATINIB, ROSUVASTATIN CALCIUM, PREGABALIN, METHYLPREDNISOLONE, METHYLPREDNISOLONE, TORSEMIDE, TORSEMIDE, |
||||
111 | 25141210 |
70 | 1 | |
Death, |
||||
RISANKIZUMAB-RZAA, |
||||
112 | 25141211 |
IN |
19 | 1 |
Death, |
||||
INOTUZUMAB OZOGAMICIN, |
||||
113 | 25141212 |
IE |
||
Death, |
||||
PALBOCICLIB, |
||||
114 | 25141222 |
MA |
2 | |
Death, |
||||
PALBOCICLIB, |
||||
115 | 25141224 |
MA |
2 | |
Death, |
||||
PALBOCICLIB, |
||||
116 | 25141225 |
US |
59 | 2 |
Death, |
||||
PALBOCICLIB, |
||||
117 | 25141227 |
MA |
2 | |
Death, |
||||
PALBOCICLIB, |
||||
118 | 25141228 |
MA |
2 | |
Death, |
||||
PALBOCICLIB, |
||||
119 | 25141231 |
CL |
79 | 2 |
Death, |
||||
PALBOCICLIB, |
||||
120 | 25141234 |
MA |
2 | |
Death, |
||||
PALBOCICLIB, |
||||
121 | 25141237 |
MA |
2 | |
Death, |
||||
PALBOCICLIB, |
||||
122 | 25141238 |
MA |
2 | |
Death, |
||||
PALBOCICLIB, |
||||
123 | 25141250 |
60 | 2 | |
Death, |
||||
SOTORASIB, |
||||
124 | 25141276 |
US |
89 | 1 |
Death, |
||||
FINERENONE, |
||||
125 | 25141284 |
US |
72 | 2 |
Death, |
||||
RIOCIGUAT, |
||||
126 | 25141309 |
US |
79 | |
Death, |
||||
OSIMERTINIB, |
||||
127 | 25141346 |
US |
64 | 1 |
Death, Product prescribing issue, |
||||
FOSTAMATINIB, FOSTAMATINIB, PREDNISONE, |
||||
128 | 25141348 |
US |
83 | 2 |
Death, |
||||
FOSTAMATINIB, FOSTAMATINIB, ALBUTEROL SULFATE, ALBUTEROL, AMLODIPINE, FUROSEMIDE, GLIMEPIRIDE, ISOSORBIDE MONONITRATE, LEVOTHYROXINE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, PANTOPRAZOLE, PREDNISONE, ROPINIROLE, SPIRONOLACTONE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, |
||||
129 | 25141374 |
US |
||
Death, |
||||
TAFAMIDIS, |
||||
130 | 25141382 |
CA |
86 | 1 |
Death, Urine analysis abnormal, Urinary sediment present, |
||||
TAFAMIDIS, HYDROXYCHLOROQUINE SULFATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FUROSEMIDE, SPIRONOLACTONE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
131 | 25141390 |
CA |
89 | 1 |
Death, |
||||
TAFAMIDIS, LANSOPRAZOLE, ROSUVASTATIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, METOPROLOL TARTRATE, METOPROLOL, RAMIPRIL, FUROSEMIDE, |
||||
132 | 25141393 |
MA |
1 | |
Death, |
||||
SUNITINIB MALATE, |
||||
133 | 25141394 |
MA |
2 | |
Death, |
||||
SUNITINIB MALATE, |
||||
134 | 25141396 |
CA |
92 | 2 |
Death, |
||||
TAFAMIDIS, |
||||
135 | 25141514 |
US |
2 | |
Death, Nausea, Insomnia, Somnolence, Vomiting, Fatigue, Decreased appetite, |
||||
FRUQUINTINIB, FRUQUINTINIB, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, ATORVASTATIN CALCIUM, LISINOPRIL, |
||||
136 | 25141690 |
US |
55 | 2 |
Death, Off label use, |
||||
RITUXIMAB, |
||||
137 | 25141691 |
AR |
||
Death, |
||||
OSIMERTINIB, |
||||
138 | 25141709 |
LT |
71 | 1 |
Death, Malaise, |
||||
DAROLUTAMIDE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, NEPAFENAC, ALLOPURINOL, RIVAROXABAN, |
||||
139 | 25141716 |
US |
2 | |
Death, |
||||
140 | 25141812 |
TH |
||
Death, Off label use, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, |
||||
141 | 25141839 |
TH |
||
Death, Off label use, |
||||
BEVACIZUMAB, ATEZOLIZUMAB, |
||||
142 | 25141873 |
|||
Death, |
||||
SCOPOLAMINE, |
||||
143 | 25141905 |
US |
87 | 2 |
Death, |
||||
LENALIDOMIDE, |
||||
144 | 25141952 |
US |
||
Death, |
||||
145 | 25142097 |
IN |
48 | 2 |
Death, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
146 | 25142165 |
US |
67 | 2 |
Death, Hypoxia, Atrial fibrillation, Rash, Neutropenia, Diarrhoea, |
||||
SACITUZUMAB GOVITECAN, |
||||
147 | 25142173 |
US |
73 | 1 |
Death, Illness, Product dose omission issue, |
||||
VELAGLUCERASE ALFA, VELAGLUCERASE ALFA, |
||||
148 | 25142239 |
US |
1 | |
Death, |
||||
FOSTAMATINIB, |
||||
149 | 25142404 |
US |
81 | 1 |
Death, Product use in unapproved indication, |
||||
BREXPIPRAZOLE, BREXPIPRAZOLE, BREXPIPRAZOLE, |
||||
150 | 25142410 |
MA |
2 | |
Death, |
||||
PALBOCICLIB, |
||||
151 | 25142524 |
US |
1 | |
Death, |
||||
OMAVELOXOLONE, |
||||
152 | 25142534 |
GB |
1 | |
Death, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLIC ACID, MYCOPHENILIC ACID, PREDNISOLONE, PREDNISOLONE ORAL, PREDNISOLONE ORAL SOLUTION, |
||||
153 | 25142561 |
US |
83 | 1 |
Death, |
||||
REGORAFENIB, |
||||
154 | 25142585 |
US |
2 | |
Death, |
||||
VALBENAZINE, |
||||
155 | 25142590 |
CA |
67 | 2 |
Death, |
||||
CLOZAPINE, |
||||
156 | 25142642 |
CA |
1 | |
Death, |
||||
CLOZAPINE, |
||||
157 | 25142671 |
CA |
58 | 2 |
Death, |
||||
CLOZAPINE, |
||||
158 | 25142753 |
TW |
||
Death, |
||||
LENALIDOMIDE, |
||||
159 | 25142786 |
TW |
||
Death, |
||||
DASATINIB, |
||||
160 | 25142801 |
US |
80 | 1 |
Death, |
||||
LENALIDOMIDE, APIXABAN, EMPAGLIFLOZIN, FINASTERIDE, FLUCONAZOLE, LEVOTHYROXINE SODIUM, METOPROLOL TARTRATE, METOPROLOL, SACUBITRIL AND VALSARTAN, |
||||
161 | 25145232 |
79 | 2 | |
Death, |
||||
RISANKIZUMAB-RZAA, |
||||
162 | 25145424 |
82 | 2 | |
Death, |
||||
APREMILAST, |
||||
163 | 25146060 |
84 | 1 | |
Death, |
||||
TOLVAPTAN, |
||||
164 | 25138196 |
US |
||
Death, |
||||
LURBINECTEDIN, |
||||
165 | 25138211 |
PL |
59 | 1 |
Death, Neutropenia, Hypomagnesaemia, Rash, Pulmonary mass, Hepatic lesion, General physical health deterioration, Hypersensitivity, |
||||
PANITUMUMAB, FLUOROURACIL, FLUOROURACIL, FLUOROURACIL, FLUOROURACIL, OXALIPLATIN, CAPECITABINE, |
||||
166 | 25138374 |
US |
92 | 1 |
Death, |
||||
LUTETIUM LU 177 VIPIVOTIDE TETRAXETAN, |
||||
167 | 25138406 |
US |
96 | 2 |
Death, Unevaluable event, Wrong product administered, |
||||
ZOLPIDEM TARTRATE, DIAZEPAM, DIAZEPAM ORAL, DIAZEPAM ORAL SOLUTION (CONCENTRATE), WARFARIN SODIUM, WARFARIN, MELATONIN, METHOCARBAMOL, METHOCARBAMOL TABLETS, ALPRAZOLAM, |
||||
168 | 25138462 |
TW |
||
Death, |
||||
LENALIDOMIDE, |
||||
169 | 25138465 |
US |
||
Death, |
||||
MACITENTAN, |
||||
170 | 25138675 |
US |
||
Death, |
||||
171 | 25138750 |
AU |
||
Death, Hospitalisation, |
||||
DENOSUMAB, |
||||
172 | 25137149 |
PK |
53 | 1 |
Death, |
||||
BEVACIZUMAB, BEVACIZUMAB, ATEZOLIZUMAB, |
||||
173 | 25137157 |
JP |
62 | 1 |
Death, |
||||
LEUPROLIDE ACETATE, CARVEDILOL, RABEPRAZOLE SODIUM, RABEPRAZOLE, DABIGATRAN ETEXILATE MESYLATE, SPIRONOLACTONE, TOLVAPTAN, AMIODARONE HYDROCHLORIDE, |
||||
174 | 25137168 |
JP |
1 | |
Death, Inappropriate schedule of product administration, |
||||
RADIUM RA 223 DICHLORIDE, |
||||
175 | 25137268 |
US |
89 | 1 |
Death, |
||||
ADALIMUMAB, |
||||
176 | 25137277 |
CA |
75 | 1 |
Death, |
||||
NINTEDANIB, |
||||
177 | 25137319 |
CA |
87 | 1 |
Death, |
||||
UPADACITINIB, |
||||
178 | 25137396 |
PL |
68 | 2 |
Death, |
||||
NINTEDANIB, |
||||
179 | 25137482 |
IE |
46 | 1 |
Death, |
||||
OLANZAPINE, HALOPERIDOL, HALOPERIDOL LACTATE, LORAZEPAM, |
||||
180 | 25137644 |
US |
||
Death, |
||||
BOSENTAN, |
||||
181 | 25137707 |
US |
91 | 2 |
Death, |
||||
ALECTINIB HYDROCHLORIDE, |
||||
182 | 25137721 |
US |
1 | |
Death, Off label use, |
||||
IBRUTINIB, |
||||
183 | 25137916 |
IN |
70 | 1 |
Death, Blood bilirubin increased, Haemoglobin decreased, |
||||
IRINOTECAN HYDROCHLORIDE, |
||||
184 | 25137927 |
FR |
||
Death, |
||||
185 | 25137928 |
US |
||
Death, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
186 | 25138106 |
US |
80 | 1 |
Death, |
||||
ABALOPARATIDE, |
||||
187 | 25140474 |
5 | 1 | |
Death, |
||||
ABIRATERONE ACETATE, ABIRATERONE, |
||||
188 | 25140875 |
76 | 2 | |
Death, |
||||
PEGINTERFERON ALFA-2A, |
||||
189 | 25141110 |
92 | 1 | |
Death, |
||||
ERYTHROPOIETIN, |
||||
190 | 25132051 |
AU |
||
Death, |
||||
DENOSUMAB, |
||||
191 | 25132107 |
CA |
74 | 2 |
Death, |
||||
USTEKINUMAB, |
||||
192 | 25132179 |
JP |
8 | 1 |
Death, Thrombocytopenia, |
||||
GILTERITINIB, GILTERITINIB, VENETOCLAX, AZACITIDINE, AZACITIDINE FOR, |
||||
193 | 25132267 |
JP |
||
Death, |
||||
GILTERITINIB, |
||||
194 | 25132273 |
US |
89 | 1 |
Death, |
||||
RIPRETINIB, |
||||
195 | 25132274 |
JP |
9 | 2 |
Death, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
196 | 25132344 |
ID |
36 | 2 |
Death, Diarrhoea, |
||||
BRENTUXIMAB VEDOTIN, PREDNISONE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, DOXORUBICIN, |
||||
197 | 25132408 |
IL |
||
Death, Brain radiation necrosis, Drug ineffective for unapproved indication, Off label use, |
||||
BEVACIZUMAB, |
||||
198 | 25132453 |
FR |
||
Death, |
||||
DURVALUMAB, TREMELIMUMAB, |
||||
199 | 25132477 |
US |
70 | 2 |
Death, |
||||
EMPAGLIFLOZIN, |
||||
200 | 25132575 |
US |
1 | 1 |
Death, Seizure, Seizure, Pneumonia, Sedation, |
||||
CANNABIDIOL, CANNABIDIOL, CANNABIDIOL, CLOBAZAM, DIVALPROEX SODIUM, |
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28